Physician profile
Jesse Lockhart
NPI 1316121106
$5,533.01
in general payments reported to CMS, 2019-2025
24 companies · $1,041 in 2025
The $1,041 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,039 · 2022: $1,127 · 2023: $1,187 · 2024: $1,139 · 2025: $1,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,366.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $1,346.75 | 2021-2025 | Xtampza, Belbuca |
| Abbvie INC. | $1,133.14 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $859.91 | 2021-2025 | Relistor |
| Scilex Pharmaceuticals INC. | $537.34 | 2021-2025 | Ztlido |
| Pfizer INC. | $335.81 | 2023-2025 | |
| Eisai INC. | $296.94 | 2021-2022 | |
| Boston Scientific Corporation | $217.34 | 2021-2025 | Wavewriter Alpha Prime 16, Na, Infinion 16 |
| Merck Sharp & Dohme LLC | $161.58 | 2021-2023 | Belsomra |
| Upsher-Smith Laboratories LLC | $116.62 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $82.03 | 2022 | |
| Arbor Pharmaceuticals, INC. | $70.01 | 2021 | |
| Amgen INC. | $64.62 | 2022 | |
| Hikma Pharmaceuticals USA | $60.61 | 2022 | |
| Biodelivery Sciences International, INC. | $38.15 | 2021 | |
| Horizon Therapeutics Plc | $31.36 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $28.77 | 2023 | Tirosint, Licart |
| Biohaven Pharmaceuticals, INC. | $27.65 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $21.78 | 2025 | |
| Medtronic, INC. | $20.45 | 2021 | |
| Valinor Pharma, LLC | $19.34 | 2025 | Movantik |
| Idorsia Pharmaceuticals US INC | $18.79 | 2022 | |
| Impel Pharmaceuticals INC. | $17.56 | 2023 | Trudhesa |
| Nalu Medical, INC. | $14.86 | 2022 | |
| Bioventus LLC | $11.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Lockhart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.